Barbanti P, Aurilia C, Cevoli S, Egeo G, et al. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study. Headache 2021 Jul 26. doi: 10.1111/head.14194.
PMID: 34309862